JXJun Xue

Jun Xue

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Xue has a total of 145 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Renal function and risk of dementia: a Mendelian randomization study

    by Haowen Huang, Yuan Ren, Jun Wang, Zhiqin Zhang, Jie Zhou, Sansi Chang, Yuelin Zhang, Jun Xue

    The burgeoning recognition of the nexus between renal functionality and the prevalence of dementia has precipitated a surge in research endeavors. This study aims to substantiate the causal relationship between kidney functionality and dementia. We utilized clinical renal function metrics from the Chronic Kidney Disease Genetics (CKDGen) Consortium and diverse dementia types (Alzheimer's disease [AD] and vascular dementia) from the FinnGen Biobank by using Mendelian randomization analysis. At the stratum of genetic susceptibility, we tested the causal relationship between variations index in renal function and the occurrence of dementia. Inverse-variance weighted (IVW) method was the main analysis, and several supplementary analyses and sensitivity analyses were performed to test the causal estimates. The findings indicate a significant correlation between each unit increase in cystatin C-based estimated glomerular filtration rate (eGFR-cys) levels was significantly associated with a reduction in the incidence of late-onset Alzheimer's disease (LOAD) (IVW: OR = 0.35, 95% CI: 0.13-0.91, p = 0.031). After adjusting for creatinine-based eGFR (eGFR-cre) and urinary albumin-to-creatinine ratio (UACR), a causal relationship was still identified between elevated levels of eGFR-cys and decreased risk of LOAD (IVW: OR: 0.08; 95% CI: 0.01-0.97, p = 0.047). Sensitivity tests demonstrated the reliability of causal estimates. The association between renal function based on cystatin C and the augmented risk of developing AD lends support to the perspective that regular monitoring of cystatin C may be a valuable investigative biomarker.


  • Understanding the role of ten-eleven translocation family proteins in kidney diseases

    by Yuelin Zhang, Jiahui Li, Li Tan, Jun Xue, Yujiang Geno Shi

    Epigenetic mechanisms play a critical role in the pathogenesis of human diseases including kidney disorders. As the erasers of DNA methylation, Ten-eleven translocation (TET) family proteins can oxidize 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), thus leading to passive or active DNA demethylation. Similarly, TET family proteins can also catalyze the same reaction on RNA. In addition, TET family proteins can also regulate chromatin structure and gene expression in a catalytic activity-independent manner through recruiting the SIN3A/HDAC co-repressor complex. In 2012, we reported for the first time that the genomic 5-hydroxymethylcytosine level and the mRNA levels of Tet1 and Tet2 were significantly downregulated in murine kidneys upon ischemia and reperfusion injury. Since then, accumulating evidences have eventually established an indispensable role of TET family proteins in not only acute kidney injury but also chronic kidney disease. In this review, we summarize the upstream regulatory mechanisms and the pathophysiological role of TET family proteins in major types of kidney diseases and discuss their potential values in clinical diagnosis and treatment.


  • Gut-derived trimethylamine N-oxide promotes CCR2-mediated macrophage infiltration in acute kidney injury

    by Yuan Ren, Zuoyuan Wang, Li You, Jie Zhou, Haowen Huang, Sansi Chang, Yuanhao Wu, Jun Xue

    Inflammation is crucial in the development of AKI and subsequent CKD following renal ischemia-reperfusion (IR) injury. Gut microbiota metabolites trigger inflammation and affect IR-induced renal damage. Yet, the driving factors and mechanisms are unclear. Trimethylamine N-oxide (TMAO), a gut-derived choline metabolite, is a strong pro-inflammatory factor that increases in patients with AKI and CKD. We hypothesized that TMAO can promote renal injury caused by IR. Mice subjected to unilateral renal IR to induce AKI and CKD were fed a high-choline diet to observe the effects of TMAO on kidney inflammation, fibrosis, and macrophage dynamics. A choline-rich diet altered the gut microbiota and elevated TMAO levels, which exacerbated IR-induced AKI and subsequent CKD. Single-cell analysis identified a distinct subset of CCR2+ macrophages derived from monocytes as key responders to TMAO, intensifying immune cell interactions and worsening renal injury. TMAO promoted sustained CCR2 expression after IR, increasing macrophage infiltration. CCR2 deletion and antagonist RS-102895 improved TMAO-induced inflammation and fibrosis, alleviated renal injury induced by IR. Our study provides valuable insights into the link between TMAO and IR-incited renal inflammation and fibrosis, emphasizing the critical role of TMAO-mediated macrophage infiltration via CCR2 as a key therapeutic target in the acute and chronic phase after IR.


  • Open Access

    Association of WBC Levels With All-Cause Mortality in ICU Patients Receiving CRRT: A Retrospective Cohort Study

    by Haowen Huang, Feng Huang, Jie Zhou, Zhiqin Zhang, Yuan Ren, Sansi Chang, Jun Xue

    Background Acute kidney injury (AKI) is a common comorbidity in the intensive care unit (ICU), with higher mortality rate among those who receive continuous renal replacement therapy (CRRT). This study aimed to investigate the association of white blood cell (WBC) levels with all-cause mortality in AKI patients undergoing CRRT. Method We conducted a post hoc analysis of ICU patient data from multiple centers in Korea. First, the levels of WBCs were classified into four groups based on quartiles. Second, the relationship between different WBC levels and mortality was investigated with the Kaplan-Meier (K-M) survival curves, Cox proportional hazards model, and generalized additivity model (GAM). Finally, we used multiple imputation to avoid bias caused by non-randomized missing data. The endpoints were short-term (28 days) and long-term (90 days) mortality. Result In our analysis, a total of 1,100 ICU patients were included. Among them, 670 (60.90%) and 781 (71.00%) died within 28 and 90 days, respectively. K-M survival curves showed that patients with the lowest WBC levels had the highest risk of mortality for both outcomes. Adjusted multivariate Cox regression analysis confirmed that compared with the reference level (quartile 2), low WBC levels increased the risk of both 28-day mortality (quartile 1, HR = 1.43, 95% CI: 1.13–1.83, P = 0.004) and 90-day mortality (quartile 1: HR = 1.32; 95% CI: 1.05-1.66, P = 0.016). GAM analysis showed a non-linear, U-shaped relationship between pre-CRRT WBC levels and all-cause mortality (non-linear P < 0.05). Conclusion The baseline WBC level is an independent predictor of prognosis for ICU patients receiving CRRT. Patients in the lowest WBC quartile had the highest risk of all-cause mortality. These results provide further evidence that early observation and intervention may have a prognostic value for these high-risk patients.

  • Open Access

    In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study

    by Yue Guo, Yifei Guo, Huajian Ying, Weien Yu, Shiqi Chen, Yao Zhang, Shenyan Zhang, Yanxue Lin, Feng Sun, Yongmei Zhang, et al.

    Introduction: The SARS-CoV-2 Omicron variant has decreased virulence and pathogenicity, yet the number of Omicron infections worldwide is unprecedentedly high, with rather high mortality and severe disease rate. Chronic kidney disease (CKD) patients are particularly vulnerable to the SARS-CoV-2 Omicron variant and have unique clinical outcomes. Methods: We retrospectively collected data from 2140 hospitalized patients with SARS-CoV-2 Omicron variant infection from March 29, 2022, to May 17, 2022. Demographic characteristics, ancillary examination results, and clinical treatments were described. Occurrence of critical COVID-19 or death and time of positive-to-negative conversion was defined as primary outcomes. The presence of COVID-19 pneumonia and the usage of respiratory or circulatory support was defined as secondary outcomes. Univariate or multivariate logistic regression analyses were performed to identify risk factors for primary outcomes. Results: 15.74% of CKD patients infected with the SARS-CoV-2 Omicron variant ended up with critical COVID-19 or death. Pre-existing CKD was a risk factor for critical COVID-19 or death and prolonged time of positive-to-negative conversion of SARS-CoV-2. Nirmatrelvir-ritonavir facilitated viral clearance among COVID-19 patients with non-severe CKD. Conclusion: We found patients with CKD and COVID-19 due to Omicron experienced worse clinical outcomes and prolonged time of positive-to-negative conversion of SARS-CoV-2 compared to patients without CKD, which helps rationalize limited medical resources and offers guidance for appropriate clinical treatments.


  • Open Access

    Characteristics and Risk Factors of Severe infection in ANCA-associated vasculitis

    by Xiaowan Liang, Tingting Wang, Xiaoye Zhu, Xiaoyi Mao, Yuanhao Wu, Lin Lu, Li You, Jun Xue

    Background: There is a close relationship between ANCA-associated vasculitis and infections. Based on a cohort of ANCA-associated vasculitis patients from East China, this study aimed todescribe the infection characteristics and prognosis of the patients, and explore the risk factors for severe infections. Methods: Relevant data from the cohort of ANCA-associated vasculitispatients (n=82) at the affiliated Huashan Hospital, Fudan University, collected between 2012 and 2021 was retrospectively reviewed to describe the basic characteristics and treatment response of the completely relieved vasculitis patients (n=63) and non-completely relieved AAV patients (n=19), and to compare the incidence of severe infections and prognosis between AAV patients with underlying infections (n=17) and those without infection(n=65). Results: 65% of the infections occurred within the first three months of AAV-induced treatment. The main site of common infection was the urinary system, with Escherichia coli being the most common pathogen. The main site of severe infections was the respiratory system, and the main pathogenic bacteria included Klebsiella pneumoniae, Candida albicans, and Aspergillus. The complete remission rate of patients with underlying infections before diagnosis of AAV was lower than that of patients without underlying infections before the onset of the disease (58.82% vs 81.84%, p=0.048), and even if the dose of immunosuppressants was reduced, the incidence of severe infections in patients with underlying infections was higher than that in patients without infections (63.64% vs 32.36%, p=0.0055). The presence of underlying infections at the time of diagnosis of AAV (HR=4.569, 95% CI=1.518-14.302, p=0.007), elevated ALT at the onset of the disease (HR=3.163, 95% CI=1.060-9.371, p=0.039), and the use of cyclophosphamide (HR=4.081, 95% CI=1.246-13.279, p=0.020) were found to be the risk factors for severe infections. Conclusions: Bacterial and fungal pneumonia are the main types of severe infection after ANCA-associated vasculitis immunosuppressive therapy. The presence of underlying infection and impaired liver and kidney function at the time of diagnosis of AAV are independent risk factors for severe infections in ANCA-associated vasculitis patients after receiving immunosuppressive therapy. Patients with underlying infection with AAV have a lower complete response rate and are still prone to severe infection after receiving reduced immunosuppressive therapy.

  • 肠源性尿毒素三甲胺-N-氧化物对终末期肾病心血管的损伤机制与治疗靶点探究

    by Yuan Ren, Zuoyuan Wang, Jun Xue

    终末期肾脏病(ESRD)患者的主要死因是心血管疾病,近年来发现三甲胺-N-氧化物(TMAO)是致病过程中的特异性危险因素之一。TMAO由膳食中胆碱、肉碱等物质经肠道微生物代谢、肝脏黄素单加氧酶催化生成。ESRD患者的肠道菌群改变,促使肠源性尿毒症毒素(TMAO、吲哚硫酸盐、吲哚-3-乙酸等)蓄积,而升高的TMAO通过促炎、增加清道夫受体表达、抑制胆固醇逆向转运等机制加速动脉粥样硬化。在这篇综述中,本研究介绍了TMAO的生理功能、代谢过程及ESRD中TMAO促进心血管疾病发生与发展的机制,回顾了目前可能用于逆转肠道微生物群紊乱的干预措施,如活性炭制剂、粪便微生物移植、膳食改善、益生元和益生菌引入,并重点探究降低肠源性尿毒症毒素TMAO的干预靶点,旨在为ESRD患者探寻更多心血管疾病治疗的可能性。


  • Open Access

    Finasteride Alleviates High Fat Associated Protein-Overload Nephropathy by Inhibiting Trimethylamine N-Oxide Synthesis and Regulating Gut Microbiota

    by Zuoyuan Wang, Li You, Yuan Ren, Xiaoye Zhu, Xiaoyi Mao, Xiaowan Liang, Tingting Wang, Yumeng Guo, Te Liu, Jun Xue

    Unhealthy diet especially high-fat diet (HFD) is the major cause of hyperlipidemia leading to deterioration of chronic kidney diseases (CKD) in patients. Trimethylamine N-oxide (TMAO) is a gut-derived uremic toxin. Our previous clinical study demonstrated that the elevation of TMAO was positively correlated with CKD progression. Finasteride, a competitive and specific inhibitor of type II 5a-reductase, has been reported recently to be able to downregulate plasma TMAO level thus preventing the onset of atherosclerosis by our research group. In this study, we established a protein-overload nephropathy CKD mouse model by bovine serum albumin (BSA) injection to investigate whether hyperlipidemia could accelerate CKD progression and the underlying mechanisms. Finasteride was administrated to explore its potential therapeutic effects. The results of biochemical analyses and pathological examination showed that HFD-induced hyperlipidemia led to aggravated protein-overload nephropathy in mice along with an elevated level of circulating TMAO, which can be alleviated by finasteride treatment possibly through inhibition of Fmo3 in liver. The 16 S rRNA sequencing results indicated that HFD feeding altered the composition and distribution of gut microbiota in CKD mice contributing to the enhanced level of TMAO precursor TMA, while finasteride could exert beneficial effects via promoting the abundance of Alistipes_senegalensis and Akkermansia_muciniphila. Immunofluorescence staining (IF) and qRT-PCR results demonstrated the disruption of intestinal barrier by decreased expression of tight junction proteins including Claudin-1 and Zo-1 in HFD-fed CKD mice, which can be rescued by finasteride treatment. Cytokine arrays and redox status analyses revealed an upregulated inflammatory level and oxidative stress after HFD feeding in CKO mice, and finasteride-treatment could alleviate these lesions. To summarize, our study suggested that finasteride could alleviate HFD-associated deterioration of protein-overload nephropathy in mice by inhibition of TMAO synthesis and regulation of gut microbiota.


  • Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment

    by Haijing Yang, Min Zhang, Yuancheng Chen, Hong Ren, Hong Zhang, Chen Yu, Jianda Lu, Li You, Jicheng Yu, Hong Liang, et al.

    Objective This study evaluated the pharmacokinetic (PK) characteristics of benapenem in subjects with mild to moderate renal impairment to provide a reference for benapenem dosing regimens in this patient population. Methods Eighteen subjects were enrolled in this study. Each subject received a single dose of benapenem intravenously (1.0 g in 100 ml of 0.9% saline) followed by blood and urine collection to measure the concentrations of benapenem and its major metabolite. PK analysis was performed to evaluate the effect of varying degrees of renal impairment on the PK characteristics of benapenem. The safety of benapenem was also evaluated. Results In subjects with normal renal function, mild renal impairment, and moderate renal impairment, the maximum plasma benapenem concentrations were 163 ± 6.58 mg/L, 138 ± 17.4 mg/L, and 134 ± 0.11 mg/L, respectively (15.3% and 17.8% lower in subjects with mild and moderate renal impairment, respectively, than in subjects with normal renal function). The areas under the plasma concentration–time curve (AUC0-inf) were 1153.67 ± 143.2 mg·h/L, 1129.17 ± 241.41 mg·h/L, and 1316.46 ± 229.83 mg·h/L, respectively (P > 0.05); the cumulative urinary excretion rates at 72 h after dosing were 52.61 ± 8.58%, 39.42 ± 8.35%, and 29.84 ± 9.15%, respectively; and the metabolic ratio (AUC0-inf_KBP-3331/AUC0-inf_benapenem) were 3.96 ± 0.35%, 5.56 ± 0.82%, and 8.24 ± 0.85%, respectively. No drug-related adverse events (AEs), serious AEs, or AEs leading to withdrawal occurred in this study. Conclusion No adjustment to benapenem dosing is needed in patients with mild to moderate renal impairment. Clinical trial registration Drug clinical trial registration and information publicity platform: http://www.chinadrugtrials.org.cn/index.html. Registration number: CTR20190760.